The National Healthcare Security Administration recently issued a notice requiring further strengthening the monitoring and disposal of the "yin-yang price" of drugs in designated retail pharmacies. The notice shows that in recent times, some designated retail pharmacies have been found to adopt "yin-yang pricing" (discriminatory pricing) behavior towards medical insurance non insurance patients, that is, selling identical drugs to medical insurance patients at a higher price than non insurance patients. According to legal requirements such as the Price Law of the People's Republic of China and the Drug Administration Law of the People's Republic of China, designated pharmacies are suspected of price fraud by selling drugs at high prices to insured patients for profit. At the same time, they violate the management requirement in the medical insurance service agreement of designated pharmacies that "unfair and discriminatory prices shall not be imposed on medical insurance insured persons", and should be seriously investigated and dealt with. Notification requirements: Pay close attention to the clues of the "yin-yang price" issue in designated pharmacies, seriously investigate and handle the "yin-yang price" issue, and do a good job in regular monitoring and governance. Medical insurance departments in various regions should effectively fulfill their main responsibilities, strengthen coordination and linkage with market supervision departments, and enhance on-site inspections and reporting verification. For designated pharmacies that violate the medical insurance service agreement by implementing "yin-yang pricing", depending on the severity of the situation and the rectification situation, measures such as interviewing the main person in charge, suspending medical insurance settlement, refusing to pay or recovering paid medical insurance funds, suspending or terminating medical insurance service agreements, and transferring to relevant departments for handling will be taken seriously to effectively safeguard the security of medical insurance funds and protect the rights and interests of the public in purchasing drugs. (New Society)